SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-expected Q3 performance and higher 2027 EBITDA outlook are driving attention, with traders pointing to stronger steel pricing and anticipating short-covering. Others caution that the outlook depends on pricing assumptions and may not resolve the companys substantial debt concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp neocloud selloff as traders question whether AI infrastructure providers can finance their expansion and earn adequate returns; speculation about forced fund liquidations is unconfirmed. The community is split between viewing the drop as an oversold buying opportunity, citing analyst support and insider purchases, and warning that the rebound could fade as sector financing concerns persist.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline: the pancreatic IMPACT study completed enrollment after multiple expansions, with traders also focused on further glioblastoma and ReSTART data. The community is broadly optimistic about clinical progress, though the studies remain early-stage and expectations for the stock are speculative.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade of CoreWeave to Buy is driving a rebound after a steep selloff over financing and debt concerns. Traders are split between expecting a recovery or short squeeze and warning that the companys heavy obligations and insider selling remain significant risks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious anniversary post and next chapter language have fueled speculation among traders about imminent REGAL trial news or a buyout, though others see it as a routine anniversary message with no new information. The central focus remains the blinded Phase 3 REGAL study, last reported at 78 of 80 events; bulls interpret the prolonged wait as a possible survival signal and look to ASH, while skeptics say the delay does not reveal the outcome.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Attention centers on Amazon-backed X-Energy and AEP studying a 12-reactor, 960-MW Xe-100 project in Indiana, reinforcing the long-term data-center power theme. Traders see Amazons backing as a reason to buy the dip, while others remain cautious amid the selloff and note that the project is still exploratory.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

EyePoints failed wet-AMD Phase 3 results are driving debate over Oculars AXPAXLI: some traders see a competitor removed, while others worry the setback undermines confidence in TKI-based treatments and could hurt OCUL as well. Bulls argue AXPAXLIs data and trial design are different, with attention also focused on its planned FDA filing.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results have put pressure on shares, with traders focused on a sharp book-value decline driven mainly by wider agency mortgage spreads and earnings that did not cover the dividend. The debate is between concern over the balance-sheet hit and dividend sustainability versus optimism that improving earnings and expanded Agency MBS holdings could benefit from a spread recovery.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

ABVX is drawing attention amid a sharp pullback that traders attribute to biotech-sector weakness and a long wait for Crohns data, expected in mid-2027, despite a targeted Q4 NDA filing for obefazimod. Some view the decline as an oversold buying opportunity, while others see limited near-term support without a confirmed buyout or fresh clinical catalyst.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on the Dows choppy performance and shifting strength versus tech-heavy indexes, with traders split between expecting rallies and warning of a correction. Treasury yields, inflation and Fed concerns, and oil-related geopolitical risks are recurring sources of market anxiety.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

About SYO